MedTrace Logo

Immune Response to Vaccinations in Hematopoietic Stem Cell Transplant Recipients

NCT03659773 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 152

Last updated 2025-09-04

No results posted yet for this study

Summary

Hematopoietic stem cell transplantation (HSCT) is a cellular therapy aiming at curing some hematological diseases. Upon transplantation, recipients experience a phase of profound immune suppression with loss of protective immunity against most infectious agents. Revaccination of HSCT recipients against vaccine-preventable infections is an important post-transplant intervention for reducing morbi-mortality. The VaccHemInf project aims at assessing the efficacy of recommended vaccines in adult recipients of HSCT, through the antibody titers reference method and a panel of immune functional assays.

Conditions

  • Vaccination
  • Hematopoietic Stem Cells

Interventions

BIOLOGICAL

immune biomarkers to evaluate vaccine response in HSCT recipients

a 38mL-blood sample will be collected before and at 3, 12 and 24 months after complete block vaccination and at 4 weeks after influenza vaccination for the ancillary study

Sponsors & Collaborators

  • BioMérieux

    collaborator INDUSTRY

  • Hospices Civils de Lyon

    lead OTHER

Principal Investigators

  • Florence ADER, Pr · Hospices Civils de Lyon

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-04-27
Primary Completion
2021-01-21
Completion
2023-01-21

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03659773 on ClinicalTrials.gov